Homocysteine and lipid peroxidation products : Important atherosclerosis risk factors in renal allograft recipients?SERAFINOWICZ, A; KUKUŁA, K; DURLIK, M et al.Transplantation proceedings. 2000, Vol 32, Num 6, pp 1367-1368, issn 0041-1345Conference Paper

Cyclosporine blood concentration at 2 hours (C₂) from drug ingestion as the best single indicator of adequate cyclosporine immunosuppression in renal allograft recipients: A four-year follow-upBACZKOWSKA, T; SERAFINOWICZ, A; LAO, M et al.Transplantation proceedings. 2002, Vol 34, Num 2, pp 556-557, issn 0041-1345Conference Paper

Cellcept enhances the rate of apoptosis in T cells after renal transplantationKASPRZYCKA, M; WIERZBICKI, P; NOWACZYK, M et al.Transplantation proceedings. 1999, Vol 31, Num 1-2, issn 0041-1345, p. 328Conference Paper

Cyclosporine pharmacokinetics in renal allograft recipients with diabetes mellitus treated with sandimmune and sandimmune neoralSERAFINOWICZ, A; GACIONG, Z; BACZKOWSKA, T et al.Transplantation proceedings. 1996, Vol 28, Num 6, pp 3140-3141, issn 0041-1345Conference Paper

Limited sampling strategy to estimate exposure to cyclosporine A in renal allograft recipients treated with sandimmun-neoralSERAFINOWICZ, A; GACIONG, Z; BACZKOWSKA, T et al.Transplantation proceedings. 1996, Vol 28, Num 6, pp 3138-3139, issn 0041-1345Conference Paper